Skip to main content

Diane Weiser

Head of Investor Relations

Cytokinetics Inc (CYTK)

Equibles does not estimate personal net worth.

Get an email with a short summary when Cytokinetics Inc publishes a filing, an earnings call transcript or a press release.

Get CYTK alerts

About Diane Weiser

Diane Weiser is recorded as Head of Investor Relations at Cytokinetics Inc (CYTK). Diane Weiser has spoken on 18 earnings calls across 1 company, most recently for Cytokinetics Inc on November 4, 2026. Cytokinetics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cytokinetics Inc includes Robert Blum (CEO), Robert I. Blum (CEO and Board Member), John T. Henderson, M.D. (Chairman) and 7 others.

Diane Weiser on recent calls

“The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com, along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments.”
Head of Investor Relations, Cytokinetics Q3 2026 Earnings Conference Call ·
“The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com, along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments.”
Head of Investor Relations, Cytokinetics Q2 2026 Earnings Conference Call ·
“Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent development. Andrew Kalos, EVP and Chief Commercial Officer, will discuss the commercial launch of a Micorzo in the U.S. and readiness in Europe.”
Head of Investor Relations, Cytokinetics Q1 2026 Earnings Conference Call ·
“Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Kalos, EVP and Chief Commercial Officer, will discuss the commercial launch of Micorzo in the U.S. and readiness in Europe.”
Head of Investor Relations, Cytokinetics Inc Q4 FY2025 Earnings Call ·
“Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Kalos, EVP and Chief Commercial Officer, will address commercial readiness activities for AFI-Campton.”
Head of Investor Relations, Cytokinetics Inc Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Cytokinetics Inc

Recent activity

Show 6 earlier activities